Clinical trial

Safety Study of Pyridostigmine in Heart Failure

NCT01415921

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2011-10-01

PhasePHASE2

Study timeline

Study start (unknown)2011-10-01Date precision: month

Registry last updated2017-07-31

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Heart Failureunresolved

Interventions

Pyridostigmine BromideDRUG · verified · RxNorm: pyridostigmine bromide

Sponsors & collaborators

NYU Langone Healthlead sponsor

Nathan Kline Institute for Psychiatric Researchcollaborator

Oklahoma State Universitycollaborator

National Heart, Lung, and Blood Institute (NHLBI)collaborator

Mapped research locations

New YorkNew York, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01415921 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.